Drug Profile
Abediterol - AstraZeneca
Alternative Names: Abediterol napadisylate; AZD-0548; LAS-100977; LAS100977 napadisylateLatest Information Update: 16 Feb 2021
Price :
$50
*
At a glance
- Originator Laboratorios Almirall
- Developer AstraZeneca
- Class Amines; Antiasthmatics; Bronchodilators; Ethers; Fluorinated hydrocarbons; Hydroxyquinolines; Ketones; Small molecules
- Mechanism of Action Beta 2 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 11 Feb 2021 Discontinued - Phase-II for Asthma (In adolescents, In children, In the elderly, In adults) in Hungary, Germany, Bulgaria, Poland (Inhalation) (AstraZeneca's pipeline, February 2021)
- 11 Feb 2021 Discontinued - Phase-II for Asthma (Inhalation) (AstraZeneca's pipeline, February 2021)
- 11 Feb 2021 Discontinued - Phase-II for Asthma in Germany (Inhalation) (AstraZeneca's pipeline, February 2021)